Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $27,527.55 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 395 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55. Following the sale, the senior vice president owned 16,899 shares in the company, valued at $1,177,691.31. This trade represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

ORKA opened at $70.88 on Thursday. Oruka Therapeutics, Inc. has a one year low of $10.77 and a one year high of $91.00. The stock’s fifty day moving average is $64.29 and its 200-day moving average is $44.86. The company has a market capitalization of $4.27 billion, a PE ratio of -36.54 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently made changes to their positions in the company. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $28,000. BNP Paribas Financial Markets raised its holdings in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada raised its holdings in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics during the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on ORKA. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Stifel Nicolaus increased their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, BTIG Research reaffirmed a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Thursday, May 14th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.